The American Journal of Medicine
Volume 121, Issue 8 , Pages 702-708 , August 2008

Incidence of Pseudomonas aeruginosa Bacteremia: A Population-Based Study

A poster of this study was presented at the Infectious Diseases Society of America 45th Annual Meeting, October 5, 2007, San Diego, Calif.

  • Majdi N. Al-Hasan, MBBS

      Affiliations

    • Department of Medicine, Division of Infectious Diseases, College of Medicine, Mayo Clinic, Rochester, Minn
    • Corresponding Author InformationRequests for reprints should be addressed to Majdi N. Al-Hasan, MBBS, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
    • ,
  • John W. Wilson, MD

      Affiliations

    • Department of Medicine, Division of Infectious Diseases, College of Medicine, Mayo Clinic, Rochester, Minn
    • ,
  • Brian D. Lahr, MS

      Affiliations

    • Department of Health Sciences Research, Division of Biostatistics, College of Medicine, Mayo Clinic, Rochester, Minn.
    • ,
  • Jeanette E. Eckel-Passow, PhD

      Affiliations

    • Department of Health Sciences Research, Division of Biostatistics, College of Medicine, Mayo Clinic, Rochester, Minn.
    • ,
  • Larry M. Baddour, MD

      Affiliations

    • Department of Medicine, Division of Infectious Diseases, College of Medicine, Mayo Clinic, Rochester, Minn

References 

  1. Pier GB, Ramphal R. Pseudomonas aeruginosa. In:  Mandell GL,  Bennett JE,  Dolin R editor. Principles and Practice of Infectious Diseases. vol 2:Philadelphia, PA: Elsevier Churchill Livingstone; 2005;p. 2587–26156th ed
  2. Diekema DJ, Pfaller MA, Jones RN, et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis. 1999;29:595–607
  3. Friedland I, Gallagher G, King T, Woods GL. Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States. J Chemother. 2004;16:437–441
  4. Kaye KS, Kanafani ZA, Dodds AE, Engemann JJ, Weber SG, Carmeli Y. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:2192–2196
  5. US Census Bureau. Olmsted County QuickFacts. http://quickfacts.census.gov/qfd/states/27/27109.htmlAccessed December 22, 2007
  6. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71:266–274
  7. Steckelberg JM, Melton LJ, Ilstrup DM, et al. Influence of referral bias on the apparent clinical spectrum of infective endocarditis. Am J Med. 1990;88:582–588
  8. Tleyjeh IM, Steckelberg JM, Murad HS, et al. Temporal trends in infective endocarditis: a population-based study in Olmsted County, Minnesota. JAMA. 2005;293:3022–3028
  9. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–140
  10. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004;140:26–32
  11. Uslan DZ, Crane SJ, Steckelberg JM, et al. Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota. Arch Intern Med. 2007;167:834–839
  12. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2003;47:2756–2764
  13. Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003;37:745–751
  14. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment (Analysis of 189 episodes). Arch Intern Med. 1996;156:2121–2126
  15. Aliaga L, Mediavilla JD, Llosa J, et al. Clinical significance of polymicrobial versus monomicrobial bacteremia involving Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2000;19:871–874
  16. Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med. 1989;87:540–546
  17. Osmon S, Ward S, Fraser VJ, Kollef MH. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest. 2004;125:607–616
  18. Scheetz MH, Bolon MK, Scarsi KK, et al. Lack of effect of fluoroquinolone resistance on mortality in subjects with Pseudomonas aeruginosa bacteraemia. J Infect. 2006;52:105–110
  19. Blot S, Vandewoude K, Hoste E, Colardyn F. Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa. J Hosp Infect. 2003;53:18–24
  20. Gales AC, Jones RN, Turnidge J, et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32(Suppl 2):S146–S155
  21. Fluit AC, Jones ME, Schmitz FJ, et al. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis. 2000;30:454–460
  22. Unal S, Masterton R, Goossens H. Bacteraemia in Europe—antimicrobial susceptibility data from the MYSTIC surveillance programme. Int J Antimicrob Agents. 2004;23:155–163
  23. Decousser JW, Pina P, Picot F, et al. Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey. J Antimicrob Chemother. 2003;51:1213–1222
  24. Koprnova J, Beno P, Korcova J, et al. Bacteremia due to Pseudomonas aeruginosa: results from a 3-year national study in the Slovak Republic. J Chemother. 2005;17:470–476
  25. Baddour LM, Hicks DV, Tayidi MM, et al. Risk factor assessment for the acquisition of fluoroquinolone-resistant isolates of Pseudomonas aeruginosa in a community-based hospital. Microb Drug Resist. 1995;1:219–222
  26. Reynolds R, Potz N, Colman M, et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother. 2004;53:1018–1032

 The study received funding from the Small Grants program at the Mayo Clinic, Rochester, Minn. The funding source had no role in the study design.

 There are no conflicts of interest for any of the authors. MNA had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

PII: S0002-9343(08)00301-X

doi: 10.1016/j.amjmed.2008.03.029

The American Journal of Medicine
Volume 121, Issue 8 , Pages 702-708 , August 2008

Article Tools

* Image Usage & Resolution